UA83418C2 - Способ получения гетероарилфенилбороновой кислоты как промежуточного соединения для получения производных фенилпиридинсульфонамида и соединения, полученные этим способом - Google Patents

Способ получения гетероарилфенилбороновой кислоты как промежуточного соединения для получения производных фенилпиридинсульфонамида и соединения, полученные этим способом Download PDF

Info

Publication number
UA83418C2
UA83418C2 UAA200609976A UAA200609976A UA83418C2 UA 83418 C2 UA83418 C2 UA 83418C2 UA A200609976 A UAA200609976 A UA A200609976A UA A200609976 A UAA200609976 A UA A200609976A UA 83418 C2 UA83418 C2 UA 83418C2
Authority
UA
Ukraine
Prior art keywords
aai
eyo
preparation
eiai
abai
Prior art date
Application number
UAA200609976A
Other languages
English (en)
Ukrainian (uk)
Inventor
Маргарет Энн Батлин
Филип Джон Хоуган
Андреас Меудт
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of UA83418C2 publication Critical patent/UA83418C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Описан способ получения соединений формулы І и IV:.
UAA200609976A 2004-02-20 2005-02-17 Способ получения гетероарилфенилбороновой кислоты как промежуточного соединения для получения производных фенилпиридинсульфонамида и соединения, полученные этим способом UA83418C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0403744.6A GB0403744D0 (en) 2004-02-20 2004-02-20 Chemical process
PCT/GB2005/000567 WO2005080403A2 (en) 2004-02-20 2005-02-17 Chemical process

Publications (1)

Publication Number Publication Date
UA83418C2 true UA83418C2 (ru) 2008-07-10

Family

ID=32040047

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200609976A UA83418C2 (ru) 2004-02-20 2005-02-17 Способ получения гетероарилфенилбороновой кислоты как промежуточного соединения для получения производных фенилпиридинсульфонамида и соединения, полученные этим способом

Country Status (32)

Country Link
US (2) US7626020B2 (ru)
EP (3) EP1718655A2 (ru)
JP (2) JP2007523906A (ru)
KR (2) KR20120036998A (ru)
CN (1) CN1922193B (ru)
AR (1) AR047810A1 (ru)
AT (1) ATE535532T1 (ru)
AU (1) AU2005214138B2 (ru)
BR (1) BRPI0507847A (ru)
CA (1) CA2555554A1 (ru)
CL (1) CL2011003138A1 (ru)
CY (1) CY1112555T1 (ru)
DK (1) DK2135873T3 (ru)
ES (1) ES2375201T3 (ru)
GB (1) GB0403744D0 (ru)
HK (1) HK1139689A1 (ru)
HR (1) HRP20120031T1 (ru)
IL (2) IL177505A (ru)
MY (1) MY142268A (ru)
NO (1) NO20064012L (ru)
PL (1) PL2135873T3 (ru)
PT (1) PT2135873E (ru)
RS (1) RS52300B (ru)
RU (1) RU2386636C2 (ru)
SA (1) SA05260017B1 (ru)
SG (1) SG153856A1 (ru)
SI (1) SI2135873T1 (ru)
TW (1) TWI347947B (ru)
UA (1) UA83418C2 (ru)
UY (1) UY28754A1 (ru)
WO (1) WO2005080403A2 (ru)
ZA (1) ZA200606579B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
JP2010507619A (ja) * 2006-10-25 2010-03-11 ノイロサーチ アクティーゼルスカブ オキサジアゾール及びチアジアゾール化合物並びにニコチン性アセチルコリン受容体調節物質としてのその使用
TW201000107A (en) * 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
ES2493916T3 (es) 2009-04-07 2014-09-12 Infinity Pharmaceuticals, Inc. Inhibidores de hidrolasa de amida de ácidos grasos
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
ES2893100T3 (es) 2015-10-12 2022-02-08 Advanced Cell Diagnostics Inc Detección in situ de variantes de nucleótidos en muestras con un elevado nivel de ruido, y composiciones y métodos relacionados con ésta

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (ru) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (ru) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (ru) * 1995-06-07 2003-08-15 Зенека Лімітед Производные n-гетероарилпиридинсульфонамида, фармацевтическая композиция, способ получения и способ противодействия влияниям эндотелина
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) * 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
WO1999048530A1 (en) 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
ATE295839T1 (de) 1998-04-29 2005-06-15 Osi Pharm Inc N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethox )-4-chinazolinamin-mesylat-anhydrat und -monohydrat
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
DK1121111T3 (da) 1998-10-15 2010-05-31 Imp Innovations Ltd Forbindelser til behandling af vægttab
DE19857765A1 (de) * 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
WO2001044239A2 (en) 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
AR031679A1 (es) 2000-02-16 2003-10-01 Astellas Pharma Inc Una composicion farmaceutica
WO2001091736A2 (en) 2000-05-31 2001-12-06 Warner-Lambert Company Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
AU2002241736A1 (en) 2000-12-21 2002-07-01 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
KR20100036390A (ko) 2001-03-06 2010-04-07 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
PE20021032A1 (es) 2001-04-11 2002-11-12 Abbott Lab Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
AU2002355266A1 (en) 2001-07-23 2003-02-17 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US20050107616A1 (en) * 2001-08-03 2005-05-19 David Gene Barrett Alpha-ketoamide derivatives as cathepsin k inhibitors
JP2003137814A (ja) 2001-08-10 2003-05-14 Takeda Chem Ind Ltd ＧｎＲＨアゴニストの併用剤
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
EP2033959B1 (de) 2003-12-20 2011-04-27 Merck Patent GmbH Tetrahydropyranochinolinderivate
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
CN1922193B (zh) 2012-12-26
BRPI0507847A (pt) 2007-07-10
TW200538451A (en) 2005-12-01
RS52300B (en) 2012-12-31
HK1139689A1 (en) 2010-09-24
PT2135873E (pt) 2012-01-16
ATE535532T1 (de) 2011-12-15
AU2005214138B2 (en) 2009-02-12
RU2006133455A (ru) 2008-03-27
WO2005080403A2 (en) 2005-09-01
RU2386636C2 (ru) 2010-04-20
KR20120036998A (ko) 2012-04-18
MY142268A (en) 2010-11-15
WO2005080403A3 (en) 2005-11-24
AU2005214138A1 (en) 2005-09-01
SG153856A1 (en) 2009-07-29
EP2135873A3 (en) 2010-03-24
KR20060129483A (ko) 2006-12-15
EP1718655A2 (en) 2006-11-08
AR047810A1 (es) 2006-02-22
IL194709A (en) 2010-12-30
EP2135873B1 (en) 2011-11-30
DK2135873T3 (da) 2012-02-13
EP2325189A3 (en) 2011-10-26
ZA200606579B (en) 2008-01-30
SA05260017B1 (ar) 2008-07-14
EP2325189A2 (en) 2011-05-25
KR101196111B1 (ko) 2012-10-30
IL177505A0 (en) 2006-12-10
SI2135873T1 (sl) 2012-03-30
CA2555554A1 (en) 2005-09-01
TWI347947B (en) 2011-09-01
IL177505A (en) 2010-12-30
CN1922193A (zh) 2007-02-28
US20100094010A1 (en) 2010-04-15
US7626020B2 (en) 2009-12-01
UY28754A1 (es) 2005-09-30
JP2007523906A (ja) 2007-08-23
CY1112555T1 (el) 2016-02-10
PL2135873T3 (pl) 2012-03-30
NO20064012L (no) 2006-11-06
ES2375201T3 (es) 2012-02-27
JP2012031174A (ja) 2012-02-16
GB0403744D0 (en) 2004-03-24
HRP20120031T1 (hr) 2012-02-29
US20080161565A1 (en) 2008-07-03
CL2011003138A1 (es) 2012-06-22
EP2135873A2 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
UA83418C2 (ru) Способ получения гетероарилфенилбороновой кислоты как промежуточного соединения для получения производных фенилпиридинсульфонамида и соединения, полученные этим способом
Pappius et al. Factors affecting the potassium content of incubated brain slices
US9364579B2 (en) Biocidal fibrous and film materials utilizing silver ion
US20060251728A1 (en) Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
ES2535867T3 (es) Composición precursora de diálisis
ES2258696T3 (es) Dispersion acuosa con accion fungicida y algicida.
AU2016274769A1 (en) Compositions and methods for tissue preservation at ambient or subnormothermic temperatures
CN102427809A (zh) 用于治疗代谢性疾病的抗炎剂和抗氧化剂轭合物
FR2619991A1 (fr) Fongicide a base de zeolite
RU2019114112A (ru) Противогрибковые сухие порошки
KR860000687B1 (ko) 안정된 방사성 진단제와 이를 위한 비방사성 캐리어
JP2019070057A5 (ru)
JP5204359B2 (ja) 透析用剤およびその製造方法
CN101491237A (zh) 四氢嘧啶在冷冻保存细胞、组织、器官中的应用
US10759748B2 (en) Compounds as L-cystine crystallization inhibitors and uses thereof
US9040261B2 (en) Compounds as L-cystine crystallization inhibitors and uses thereof
CN113519506B (zh) 一种无蛋白、无dmso细胞冻存液、应用及其制备方法
Li et al. Improved biocompatibility and antibacterial property of zinc alloy fabricated with γ-polyglutamic acid-g-dopamine/copper coatings for orthopedic implants
Scheie et al. Combined effect of xylitol, NaF and ZnCl2 on growth and metabolism of Streptococcus sobrinus OMZ 176
US9526675B2 (en) Dentinal tubule sealing material
Wagner Donor heart preservation and perfusion
CN111533759A (zh) 一种手性银纳米簇聚集体的制备方法及其应用
WO2013115322A1 (ja) 細胞の保存方法
CN208144192U (zh) 一种高效稳定型孵化器
Zieger et al. Factors influencing survival of mammalian cells exposed to hypothermia: V. Effects of hepes, free radicals, and H2O2 under light and dark conditions